284 related articles for article (PubMed ID: 20406163)
1. Fenofibrate and metabolic syndrome.
Kraja AT; Province MA; Straka RJ; Ordovas JM; Borecki IB; Arnett DK
Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):138-48. PubMed ID: 20406163
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
4. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
[TBL] [Abstract][Full Text] [Related]
5. Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.
Feitosa MF; An P; Ordovas JM; Ketkar S; Hopkins PN; Straka RJ; Arnett DK; Borecki IB
Atherosclerosis; 2011 Apr; 215(2):435-9. PubMed ID: 21324458
[TBL] [Abstract][Full Text] [Related]
6. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
8. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
10. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
Pharmacogenet Genomics; 2009 Feb; 19(2):161-9. PubMed ID: 19057464
[TBL] [Abstract][Full Text] [Related]
12. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Foucher C; Rattier S; Flavell DM; Talmud PJ; Humphries SE; Kastelein JJ; Ayyobi A; Pimstone S; Frohlich J; Ansquer JC; Steiner G;
Pharmacogenetics; 2004 Dec; 14(12):823-9. PubMed ID: 15608561
[TBL] [Abstract][Full Text] [Related]
13. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
14. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
15. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
16. [How to treat dyslipidemia in patients with metabolic syndrome].
Soška V
Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
[TBL] [Abstract][Full Text] [Related]
18. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
19. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
20. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
